Home

overview

Join us for a symposium on bispecific antibodies for relapsed-refractory diffuse large B-cell lymphoma designed to encourage the exchange of ideas between leaders in the field and attendees. Experts will discuss clinical trial data, adverse event management, and current treatment approaches. This program will include a dynamic panel discussion and rapid-fire Q&A as well as an interactive audience Q&A.

Not an official event of the 2024 ASCO® Annual Meeting. Not sponsored, endorsed, or accredited by ASCO®, Association for Clinical Oncology, or Conquer Cancer® the ASCO Foundation.

faculty

MODERATOR

Loretta J. Nastoupil, MD

Deputy Chair

Section Chief, Indolent Lymphoma and New Drug Development

Director, Lymphoma Outcomes Database

The University of Texas

MD Anderson Cancer Center

Houston, Texas

PANELIST

Reid Merryman, MD

Assistant Professor

Dana-Farber Cancer Institute

Boston, Massachusetts

PANELIST

Lorenzo Falchi, MD

Assistant Attending

Lymphoma Service

Memorial Sloan-Kettering Cancer Center

New York, New York

AGENDA

6:15 pm

Dinner and Registration

6:45 pm

Welcome and Introductions

Loretta J. Nastoupil, MD

6:50 pm

Deep Dive Into Bispecific Agents, Part I

Lorenzo Falchi, MD

7:05 pm

Deep Dive Into Bispecific Agents, Part II

Reid W. Merryman, MD

7:20 pm

Rapid-Fire Expert Q&A

All Faculty

7:35 pm

Closing Remarks and Q&A

All Faculty

GOAL STATEMENT

The goal of this activity is for learners to be better able to differentiate between available bispecific antibodies used in the treatment of R/R DLBCL and integrate evidence-based treatment strategies.

TARGET AUDIENCE

This activity is intended for hematologists/oncologists, oncology nurses, oncology nurse practitioners, oncology physician assistants, and oncology pharmacists.

LEARNING OBJECTIVES

Upon completion of this activity, participants will:

Have increased knowledge regarding the

Utilization differences between available bispecific antibodies used to treat R/R DLBCL

Have greater competence related to

Selecting therapy for R/R DLBCL with bispecific antibodies
Managing adverse events of bispecific antibody therapy

Demonstrate greater confidence in their ability to

Incorporate the latest clinical data to optimize the safe usage of bispecific antibodies for R/R DLBCL

ACCREDITATION STATEMENT

In support of improving patient care, Medscape, LLC is jointly accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

For Physicians

Medscape, LLC designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credits^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

For Nurses

Awarded 1.0 contact hour(s) of nursing continuing professional development for RNs and APNs; (To be updated) contact hours are in the area of pharmacology.

For Pharmacists

Medscape designates this continuing education activity for 1.0 contact hour(s) (0.100 CEUs) (Universal Activity Number: JA0007105-0000-24-145-L01-P).

Expert Treatment Approaches CME/CNE/CPE